Aimmovig Adverse Event Report 2018

$19.99

This report includes data from the FDA’s Adverse Events Reports for 2018.  We removed reports where the subject of the report was taking only this drug. This report provides the following fields:

  • ID
  • Patient Summary
  • Patient Gender
  • Patient Age
  • Drug Products
  • Drug Reactions

Description

Aimovig (erenumab) is a monoclonal antibody that blocks the activation of a certain protein that can produce a migraine attack. This protein, called calcitonin gene- related peptide (CGRP), can cause blood vessels to dilate and cause inflammation and migraine headache pain. Aimovig is a prescription medicine used for the preventive treatment of migraine in adults. Aimovig may also be used for purposes not listed in this medication guide. https://www.drugs.com/aimovig.html

Contact US

484-352-2642

What is an Adverse Event Report?

The FDA Adverse Event Reporting System (FAERS) is a database that contains adverse event reports, medication error reports and product quality complaints resulting in adverse events that were submitted to FDA.